Background: Loneliness is a major health issue among older adults. The aim of this study was to assess the relationship between loneliness, in its social and emotional facets, and the cognitive (language), and behavioral/psychological functioning as well as quality of life (QoL) in people with mild and moderate dementia, i.e., considering dementia severity as an individual characteristic.
Methods: This cross-sectional study involved 58 people with mild dementia and 55 people with moderate dementia. Participants completed the Social and Emotional Loneliness scale, along with measures assessing their language skills, the frequency and severity of their behavioral and psychological symptoms, and their QoL.
Results: Socio-demographic characteristics and depression, but not loneliness or its social and emotional facets, contributed to explain participants' behavioral and psychological symptoms, regardless of dementia severity. Loneliness explained, though to a small extent (8% of variance), language skills in people with moderate dementia, with social loneliness only accounting for language skills (18% of variance) in this group. Loneliness also modestly accounted for dysphoria symptoms in both the mildly and moderately impaired (6% and 5% of variance, respectively) individuals with social loneliness predicting dysphoric mood in the former group only (7% of variance). Loneliness also explained, to a larger extent, QoL in both the mildly impaired and moderately impaired individuals (27% and 20% of variance, respectively), its social facet predicting QoL in the mildly impaired (30% of variance), and its emotional facet in the moderately impaired (21% of variance) group.
Conclusion: These findings suggest that loneliness and its facets have a clear impact on perceived QoL, and influence the language skills and dysphoria symptoms of people with dementia, to a degree that depends on dementia severity. The assessment of loneliness and its facets in people with dementia considering dementia severity, and the promotion of social inclusion to reduce it should be considered by professionals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667624 | PMC |
http://dx.doi.org/10.1186/s12877-022-03517-2 | DOI Listing |
Alzheimers Dement
December 2024
Bonn-Aachen International Center for IT (b-it), Bonn, Germany.
Background: Alzheimer's Disease (AD) is associated with sleep disturbances. Moreover, individuals with sleep disturbances have been reported to have a higher risk for developing AD. The measurement of sleep behavior therefore opens the opportunity for a potential digital biomarker of AD.
View Article and Find Full Text PDFBackground: Tau-PET tracers allow for in vivo Braak staging of individuals in the Alzheimer's disease (AD) continuum. The impact of tracers' characteristics for Braak staging using tau-PET remains unclear. Therefore, we performed a head-to-head comparison of Braak staging using first- and second-generation tau-PET tracers.
View Article and Find Full Text PDFBackground: Recent research by Da et al. (2023) has demonstrated that non-invasive gamma sensory stimulation can reduce brain white matter atrophy and myelin content loss. The impact on the Corpus Callosum (CC), the brain's largest commissural white matter tract essential for hemispheric connectivity, remains unexplored.
View Article and Find Full Text PDFBackground: An easy and reliable method for detection of Alzheimer's Disease (AD) and mild cognitive impairment (MCI) is critical for clinical trial enrollment. In the era of amyloid-lowering therapies, there is a need to identify individuals likely to have amyloid to enrich recruitment and lower costs related to amyloid PET. In addition, a subset of cognitively normal individuals have amyloid deposition (Preclinical AD) but to date there is no cognitive assessment or screening method that can detect these individuals in the absence of expensive biomarkers.
View Article and Find Full Text PDFBackground: Increasing evidence supports the use of plasma biomarkers of amyloid, tau, neurodegeneration and neuroinflammation for diagnosis of dementia. However, their performance for positive and differential diagnosis of dementia with Lewy bodies (DLB) in clinical settings is still uncertain.
Method: We conducted a retrospective biomarker study in two tertiary memory centers, Paris Lariboisière and CM2RR Strasbourg, France, enrolling patients with DLB (n=104), Alzheimer's disease (AD, n=76) and neurological controls (NC, n=27).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!